Cancer risk among individuals with mental illness - a systematic review and meta-analysis of nordic register-based prospective studies.
Translational psychiatry · 2026
Abstract originale
Although cancer patients have a high burden of mental illness, it is less clear whether patients with mental illness experience a higher-than-expected cancer risk. This systematic review investigated the associations between a wide range of types of mental illness and subsequent cancer risk. Five electronic databases were searched for articles published from database initiation to October 24, 2024. Studies using nationwide Nordic register data to conduct a prospective analysis of the association between mental illness diagnosis and cancer incidence were included. When data from three or more countries were available for a given type of mental illness, random effects meta-analyses were performed; otherwise, narrative syntheses were conducted. A total of 7,767 non-duplicate articles were screened, of which 20 were included. Meta-analyses showed no association between schizophrenia diagnosis and overall cancer risk; however, a high level of heterogeneity was detected between studies. Individuals with schizophrenia appeared to have a higher risk of breast cancer (pooled standardized incidence ratio [SIR]: 1.28, 95% confidence interval [CI]: 1.08-1.52), and lower risks of rectal cancer (pooled SIR: 0.75, 95% CI: 0.59-0.95) and prostate cancer (pooled SIR: 0.53, 95% CI: 0.48-0.59), compared to individuals in the general population. A higher risk of overall cancer was observed for mood, anxiety, and stress-related disorders, as well as autism and intellectual disability, in multiple studies; however, the results differed by cancer types and sex. In summary, these findings suggest an altered risk of cancer among individuals with mental illness living in Nordic countries. Further research is needed to enable the development of targeted cancer prevention strategies to reduce mental health disparities in cancer protection.
Parole chiave
Leggi il testo integrale originale
Testo estratto dalla pubblicazione: sono esclusi immagini, media, supplementi e parti soggette a diritti distinti.
Cancer risk among individuals with mental illness – a systematic review and meta-analysis of nordic register-based prospective studies
Although cancer patients have a high burden of mental illness, it is less clear whether patients with mental illness experience a higher-than-expected cancer risk. This systematic review investigated the associations between a wide range of types of mental illness and subsequent cancer risk. Five electronic databases were searched for articles published from database initiation to October 24, 2024. Studies using nationwide Nordic register data to conduct a prospective analysis of the association between mental illness diagnosis and cancer incidence were included. When data from three or more countries were available for a given type of mental illness, random effects meta-analyses were performed; otherwise, narrative syntheses were conducted. A total of 7,767 non-duplicate articles were screened, of which 20 were included. Meta-analyses showed no association between schizophrenia diagnosis and overall cancer risk; however, a high level of heterogeneity was detected between studies. Individuals with schizophrenia appeared to have a higher risk of breast cancer (pooled standardized incidence ratio [SIR]: 1.28, 95% confidence interval [CI]: 1.08-1.52), and lower risks of rectal cancer (pooled SIR: 0.75, 95% CI: 0.59-0.95) and prostate cancer (pooled SIR: 0.53, 95% CI: 0.48-0.59), compared to individuals in the general population. A higher risk of overall cancer was observed for mood, anxiety, and stress-related disorders, as well as autism and intellectual disability, in multiple studies; however, the results differed by cancer types and sex. In summary, these findings suggest an altered risk of cancer among individuals with mental illness living in Nordic countries. Further research is needed to enable the development of targeted cancer prevention strategies to reduce mental health disparities in cancer protection.
Introduction
Cancer and mental illness constitute two major contributors to the global burden of disease. In 2020, there were 19.3 million new cancer cases and ten million cases of cancer-related death worldwide [1]. Despite advances in cancer diagnosis and treatment, and the resulting continual improvements in cancer survival, over the past decades, the health burden due to cancer is still substantial. The average years of life lost due to cancer were 15.2 in 2020 and the global economic cost for cancer is estimated at as high as $25.2 trillion from 2020 to 2050 [2]. Mental illness, including psychiatric disorders (e.g., schizophrenia, mood disorders, anxiety, and stress-related disorders) and neurodevelopmental conditions (e.g., autism, attention deficit hyperactivity disorder [ADHD], and intellectual disability), is also one of the most common causes of morbidity today. In 2019, approximately 970 million people worldwide were reported to experience mental illness, and the global number of disability-adjusted life-years due to mental illness increased from 80.8 million in 1990 to 125.3 million in 2019 [3]. In total, mental illness was estimated to cost the world economy approximately $2.5 trillion per year in poor health and reduced productivity in 2010, a cost estimated to increase to approximately $6 trillion per year by 2030 [4].
Given their high prevalence, comorbidity of cancer and mental illness is inevitable. It is well established that cancer patients have increased risks for mental illness. We and others have, for instance, demonstrated an increased risk of mental illness during the entire survivorship of cancer patients, especially immediately following cancer diagnosis [5, 6]. Although it is difficult to discern the exact reasons for this risk increment, severe psychological distress experienced during cancer diagnosis and treatment, in addition to cancer biology itself and side effects of cancer treatment, might play a role. Importantly, we have also demonstrated that comorbid mental illness before or after cancer diagnosis increases the risk of overall and cancer-specific mortality [7, 8], as well as other severe adverse outcomes (e.g., sepsis) after cancer diagnosis [9]. On the other hand, conflicting findings have been observed regarding the risk of cancer among individuals with mental illness [10]. Previous systematic reviews and meta-analyses have investigated cancer incidence among individuals with schizophrenia [11, 12], depression or anxiety [13], and anorexia nervosa [14], demonstrating high levels of heterogeneity between studies. Study results also vary by cancer type, sex, and the type of mental illness. Namely, the risk of overall cancer was shown to be slightly increased among individuals with anxiety or depression, slightly decreased among individuals with schizophrenia, and unaltered among individuals with anorexia nervosa. As a comprehensive understanding of cancer risk among individuals with mental illness is essential for effective cancer prevention strategies, we aimed to conduct an updated systematic review and meta-analysis of cancer risk among individuals with a broader range of mental illness types, including both psychiatric and neurodevelopmental conditions.
Methods
Search strategy and selection criteria
We conducted a systematic review and meta-analysis of the risk of cancer after the diagnosis of mental illness, according to a protocol registered on PROSPERO prior to formal initiation of the review (identifier: CRD42024593919). Due to the extensive quantity of literature published, using varying quality of data, we subsequently restricted our review to studies using nationwide Nordic register data, to ensure minimal risk of bias.
As such, studies were eligible for inclusion if they used Nordic registers to define both the exposure and outcome variables, using diagnostic codes, for the entire national population. One or more of the following types of mental illness must have been included as the exposure variable(s): schizophrenia, mood disorders (including bipolar disorder and depression), anxiety (including obsessive-compulsive disorder [OCD]) and stress-related disorders, eating disorders, and neurodevelopmental conditions (including autism, ADHD, and intellectual disability). Studies were eligible for inclusion if they used the risk of ‘any cancer’ as a combined outcome, and/or studied one or more of the following most prevalent cancer types in Europe: breast, colorectal, lung, prostate, urinary bladder, uterine, kidney, or pancreatic cancer [15]. Additionally, studies must have conducted prospective analysis of the association between the exposure (diagnosis of mental illness) and the outcome (cancer incidence) (i.e., cohort/nested case-control studies), quantified using one of the following measures of association: odds ratio (OR), hazard ratio (HR), relative risk (RR), risk ratio (RR), incidence rate ratio (IRR), standardized incidence ratio (SIR), or standardized morbidity ratio (SMR).
Studies were excluded if they focused on paediatric or elderly populations, or cancer outcomes (e.g., survival or treatment) other than incidence. Studies using other designs (i.e., cross-sectional studies, case studies, case series, randomized controlled trials [RCTs], or qualitative studies), systematic reviews, conference abstracts, and studies not published in English or subsequently translated to English were also excluded.
We searched five electronic databases (PubMed, Embase, PsycINFO, Web of Science, and Scopus) on October 24, 2024, to identify eligible studies published since database initiation. Search terms were selected after reviewing keywords in known eligible literature. The full search strategies used for each database are displayed in Supplementary Table 1.
Title and abstract screening and full text review were conducted by XX and GM, with 20% of articles independently screened by FS at each stage. Any disagreement was resolved by discussion with MMB and FF. Reference lists of all relevant systematic reviews, and all included studies, were searched for additional eligible studies. Study authors were contacted if articles contained missing data for the association measures.
Data analysis
Data were extracted by XX, FS and MMB, using a pre-piloted data extraction sheet, and all extracted data were checked for accuracy by FF. Key study characteristics including country of study, study population, definitions of exposure and outcome variables, age, and sex were extracted.
Risk of bias was assessed by MMB and FF using the Joanna Briggs Institute (JBI) critical appraisal checklist for cohort studies [16]. This tool contains 11 questions to assess the potential risk of bias in specific study domains, each of which can be answered with ‘yes’, ‘no’, ‘unclear’, or ‘not applicable’. As certain questions did not apply to all types of study design, we calculated a total score for each study according to the number of questions for which ‘yes’ had been selected, divided by the number of applicable questions for the respective study, which was then converted into a percentage score. Based on previous literature [17], studies were classified as being at low risk of bias if they scored 70% or above, at moderate risk of bias if they scored between 50-60%, and at high risk of bias if they scored under 50%.
Random effects meta-analyses were conducted when studies from at least three countries were available for the relevant exposure (i.e., mental illness type). Where multiple studies from each country were performed using the same exposure and outcome, studies were selected for meta-analyses based on the measure of association used and the date of publication. For the main meta-analyses models we included only studies that used standardized incidence ratio (SIR), as this was the association measure used in at least one study from all included countries. We also conducted a sensitivity analyses, in which the most recent study from each country was included in each meta-analysis, regardless of the measure of association used. This allowed us to ascertain whether the observed associations persisted in the most recently conducted studies. However, bias introduced by combining different estimands with different reference groups may have reduced the validity of these pooled estimates. The maximally adjusted models in each study were included in the meta-analyses. Meta-analyses were performed using STATA version 18, and heterogeneity was measured using the I² statistic. Publication bias was assessed using the Egger’s test. For exposures not eligible for meta-analysis, a narrative synthesis was conducted.
Role of the funding source
The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report.
Results
From the database searches, 7769 non-duplicate articles were identified, of which 190 full texts were reviewed for eligibility, and 20 were included in the systematic review (Fig. 1).
Study characteristics
The key characteristics of the 20 included studies are displayed in Table 1. A total of ten studies [18–27] (50%) were from Sweden, eight studies [28–35] (40%) were from Denmark, one study [36] was from Finland, and one was a multinational Nordic study [37] using data from Sweden, Denmark, and Finland.Table 1Key characteristics of the 20 included studies.
Study Country Study period Study design Study population size Measure of association used Age-based eligibility criteria Average follow-up time (years) % female Risk of bias
Crump et al., [18]a Sweden 2003-2009 Cohort 6,587,036 individuals (including 8277 with diagnosis of schizophrenia) HR Aged ≥25 years NR 42 Low
Crump et al., [19]b Sweden 2003-2009 Cohort 6,097,834 (including 6618 with diagnosis of bipolar disorder) HR Aged ≥20 years NR 59 Low
Dalton et al., [28] Denmark 1969-1995 Cohort 89,491 individuals with diagnosis of mood disorder+ SIR Aged ≥15 years 12.5 64 Low
Dalton et al., [29] Denmark 1970-1997 Cohort 1,336,313 individuals (including 7541 with diagnosis of schizophrenia) RR Born after 1935, aged ≥25 years 9.9 100 (female-only study) Low
Dalton et al., [30] Denmark 1969-1995 Cohort 22,766 individuals with diagnosis of schizophrenia+ SIR Aged ≥15 years 12.8 43 Low
Gradus et al., [31] Denmark 1995-2011 Cohort 4131 individuals with diagnosis of PTSD+ SIR Aged ≥16 years 7.6 60 Low
Ji et al., [20] Sweden 1965-2008 Cohort 59,232 individuals with diagnosis of schizophrenia+ SIR None NR 46 Low
Karamanis et al., [21] Sweden 1973-2003 Cohort 6009 indidviduals with diagnosis of anorexia nervosa+ SIR Aged 10-40 years 15.2 100 (female-only study) Low
Lichtermann et al., [36] Finland 1971-1996 Cohort 26,996 individuals with diagnosis of schizophrenia+ SIR Born between 1940-1969 16.5 42 Low
Liu et al., [22] Sweden 1974-2016 Cohort 3,531,305 individuals (including 27,956 with diagnosis of intellectual disability) HR Born between 1974-2013 8.9 (median) 42 Low
Liu et al., [23] Sweden 1987-2016 Cohort 2,354,594 individuals (including 40,334 with diagnosis of autism) OR Born between 1987-2013 NR 32 Low
Lu et al., [24] Sweden 1990-2009 Nested case-control 94,626 breast cancer cases and 2,838,765 cancer-free controls OR Aged ≥18 years 15.2 100 (female-only study) Low
Mellemkjaer et al., [32] Denmark 1970-1996 Cohort 2337 individuals diagnosed with anorexia nervosa+ SIR Aged 7-50 years 11.7 (females), 12.5 (males) 92 Low
Mellemkjaer et al., [37] Sweden, Denmark & Finland 1969-2011* Cohort 265,581 individuals (including 24,332 with diagnosis of anorexia nervosa) IRR Aged 10-50 years 12.6 93 Low
Michels et al., [25] Sweden 1965-2000 Cohort 7303 individuals with diagnosis of anorexia nervosa+ SIR Aged <40 years 13.3 100 (female-only study) Low
Momen et al., [33] Denmark 2000-2016 Cohort 5,940,299 individuals (including 698,874 with diagnosis of at least one mental illness++) HR Born between 1900-2015, aged ≥1 year NR 50 (of entire study population) Low
Mortensen, [34] Denmark 1957-1984 Cohort 6152 indivdiauls with diagnosis of schizophrenia+ SIR None NR 52 Moderate
Pettersson et al., [26] Sweden 1990-2013 Cohort 111,306 individuals with diagnosis of schizophrenia IRR Aged ≥15 years 12.8 53 Low
Tian et al., [27] Sweden 1981-2016 Cohort 1,799,637 indidviduals (including 167,836 with diagnosis of stress-related disorders) HR Born between 1932-2011, aged ≥5 years 7.1 62 Low
Wium-Andersen et al., [35] Denmark 1997-2018 Cohort 413,844 individuals (including 246,283 with diagnosis of mood disorder) HR Aged ≥18 years 9.5 51 Low
PTSD: post-traumatic stress disorder; HR hazard ratio, SIR standardized incidence ratio, OR odds ratio, IRR incidence rate ratio, RR relative risk, NR not reported
a Crump C, Winkleby MA, Sundquist K, Sundquist J. Comorbidities and mortality in persons with schizophrenia: a Swedish national cohort study. American Journal of Psychiatry. 2013;170[3]:324-333.
b Crump C, Sundquist K, Winkleby MA, Sundquist J. Comorbidities and mortality in bipolar disorder: a Swedish national cohort study. JAMA psychiatry. 2013;70[9].
*study period varied by country - Sweden: 1973-2010, Denmark: 1970-2011, Finland: 1969-2009.
+Cancer incidence compared to incidence rates in respective national population.
++ relevant mental illness for this review included: schizophrenia, mood disorders (including bipolar and depression), anxiety and stress-related disorders, eating disorders, and neurodevelopmental disorders (including attention deficit hyperactivity disorder [ADHD] and autism spectrum disorder [ASD]).
Average follow-up time refers to mean, unless otherwise specified. Average follow-up time and % female columns refer to exposed individuals, unless otherwise specified.
The majority of included studies (N = 19, 95%) were cohort studies, while one was a nested case-control study. Of the 19 included cohort studies, nine compared cancer incidence in exposed vs unexposed participants, using hazard ratios (HR), relative risk (RR), incidence rate ratios (IRR) or odds ratios (OR). The ten remaining cohort studies compared cancer incidence between exposed participants and the total national population of interest, using standardized incidence ratios (SIR) or incidence rate ratios (IRR). The nested case-control study compared odds of mental illness between cases of breast cancer and controls, using OR.
Age-based eligibility criteria were used in 18 (90%) of the included studies. Average follow-up time was reported in 14 studies (70%), with a mean/median ranging from 7.1 years to 16.5 years. The proportion of female participants was reported in all studies, ranging from 32% to 100%. Of the 20 included studies, 19 were classified as being at low risk of bias, and one at moderate risk of bias, according to the JBI Critical Appraisal Checklist for Cohort Studies (Supplementary Table 2). However, seven (35%) of the included studies did not clearly describe whether participants were free of the outcome at study start. For the identification of mental illness, 11 studies (55%) used data from both inpatient and outpatient care records, eight studies (40%) used inpatient care records only, and one study used data from inpatient care and disability pension records (Supplementary Table 3). The model results from each study, including the covariates adjusted for, are displayed in Supplementary Tables 4 and 5, and differed greatly between studies.
Schizophrenia
In total, nine studies from Denmark, Sweden, and Finland investigated the association between diagnoses of schizophrenia and subsequent cancer risk [18, 20, 24, 26, 29, 30, 33, 34, 36]. Meta-analyses of the most recent study from each country utilizing SIR showed no consistent association between countries, as the levels of heterogeneity between studies were high (I2: 97.4%, p < 0.001) (Fig. 2). Individuals with a diagnosis of schizophrenia appeared to have a higher risk of breast cancer (pooled SIR: 1.28, 95% CI: 1.10-1.50), and a lower risk of both rectal cancer (pooled SIR: 0.79, 95% CI: 0.69-0.90) and prostate cancer (pooled SIR: 0.53, 95% CI: 0.48-0.59). However, the levels of heterogeneity remained high (e.g., I²: 82% for breast cancer).
Similar associations were observed in the sensitivity analyses, in which the most recent study from each country was included in each meta-analysis, regardless of the measures of association used, i.e., combining HR, SIR, IRR, and OR to calculate the pooled estimates (Supplementary Figure 1). Sex-stratified meta-analyses showed a difference in the association between diagnoses of schizophrenia and risk of any cancer in men, compared to women; however, none of the results from the sex-stratified meta-analyses were statistically significant, and levels of heterogeneity between studies were high (Fig. 3). No evidence was found for publication bias in the meta-analyses (Supplementary Table 6).
Mood disorders
Of the included studies, four studies conducted in Denmark and Sweden investigated the associations between diagnoses of mood disorders and subsequent cancer risk. One study [33] showed a slightly higher risk of any cancer among individuals with a diagnosis of any mood disorder (HR: 1.03, 95% CI: 1.02-1.05), while another study [19] observed no association between bipolar disorder and the risk of any cancer in either males or females. A further study [28] categorized mood disorders into bipolar disorder and other affective disorders, finding that individuals with other depressive disorders had a higher risk of any cancer (SIR: 1.14, 95% CI: 1.10-1.17), lung cancer (SIR: 1.59, 95% CI: 1.47-1.72), colon cancer (SIR: 1.16, 95% CI: 1.03-1.30), pancreatic cancer (SIR: 1.52, 95% CI: 1.27-1.79), and urinary bladder cancer (SIR: 1.23, 95% CI: 1.07-1.41), while individuals with bipolar disorder had a lower risk of rectal cancer (SIR: 0.79, 95% CI: 0.68-0.92). The remaining study [35] categorized mood disorders into bipolar disorder, major depressive disorder, and other affective disorders, finding that individuals with major depressive disorder had a higher risk of lung cancer (HR: 1.12, 95% CI: 1.04-1.20), and a slightly lower risk of prostate cancer (HR: 0.91, 95% CI: 0.83-0.99).
Anxiety and stress-related disorders
In total, three studies from Denmark and Sweden analyzed associations between diagnoses of anxiety or stress-related disorders and subsequent cancer risk. One study [33] used a broad definition of anxiety and stress-related disorders, finding a higher risk of any cancer among individuals with diagnoses of such disorders in the overall study population (HR: 1.13, 95% CI: 1.11-1.15), and among males and females separately. Another study [27] used stress-related disorders as the exposure, finding a higher risk of any cancer (HR: 1.03, 95% CI: 1.01-1.06), lung cancer (HR: 1.25, 95% CI: 1.15-1.37) and pancreatic cancer (HR: 1.50, 95% CI: 1.28-1.75), but a lower risk of prostate cancer (HR: 0.89, 95% CI: 0.82-0.96) among individuals with such diagnoses. The remaining study [31], which focused only on diagnoses of post-traumatic stress disorder (PTSD), found no association with the risk of any cancer or specific cancer types (including breast and colon cancers).
Eating disorders
A total of five studies have investigated associations between diagnoses of eating disorders and subsequent cancer risk. One study [33] defined eating disorders as diagnoses of anorexia nervosa or bulimia nervosa, finding that individuals with such diagnoses had a higher risk of any cancer (HR: 1.26, 95% CI: 1.14-1.39). However, sex-stratified analysis showed that the association was only observed in females. The remaining four studies [21, 25, 32, 37] used diagnoses of anorexia nervosa as the study exposure, finding no association between such diagnoses and the risk of any cancer. However, another study [37] did observe a higher risk of lung cancer (IRR: 1.60, 95% CI: 1.10-2.40) among females diagnosed with anorexia nervosa, whereas two additional studies [25, 37] demonstrated a lower risk of breast cancer (e.g., IRR: 0.60, 95% CI: 0.50-0.80) among females with such diagnoses.
Neurodevelopmental conditions
One study [23], conducted in Sweden, investigated the association between diagnoses of autism and subsequent cancer risk, finding a higher risk of any cancer among individuals with such diagnoses (OR: 1.30, 95% CI: 1.20-1.50). Two studies, conducted in Sweden and Denmark, analyzed associations between diagnoses of intellectual disability and subsequent risk of cancer. One study [22] showed a higher risk of any cancer among individuals with intellectual disability (HR: 1.57, 95% CI: 1.35-1.82). Although the other study [33] found no association between such diagnoses and risk of any cancer in the total study population. Sex-stratified analyses revealed contrasting trends by sex, namely a lower risk of any cancer among men with intellectual disability (HR: 0.81, 95% CI: 0.73-0.90) but a higher risk of any cancer for women with such diagnoses (HR: 1.15, 95% CI: 1.04-1.27).
Discussion
This systematic review of 20 prospective Nordic register-based studies indicates an altered risk of cancer among individuals with mental illness, compared to the general population. However, findings varied greatly by the type of mental illness and cancer type. Sex variations were also observed. Although no association between schizophrenia and overall cancer risk was found in the meta-analyses, our site-specific cancer findings align with previous systematic reviews, showing a higher risk of breast cancer, and a lower risk of prostate and rectal cancer among individuals with schizophrenia [11, 12]. Specific types of mood, anxiety, and stress-related disorders were associated with an increased risk of overall cancer in some studies, supporting results from a previous systematic review of cancer risk among individuals with depression or anxiety [13]. Individuals with eating disorders did not have an altered risk of overall cancer in the majority of the included studies; however, a reduced risk of breast cancer was observed among women, aligning with a previous systematic review of cancer risk among individuals with anorexia nervosa [14]. Furthermore, findings from the included studies suggested a higher risk of overall cancer among individuals with autism or intellectual disability. There is currently limited knowledge on the risk of cancer among individuals with other neurodevelopmental conditions, including ADHD, as well as specific types of anxiety disorders (e.g., obsessive-compulsive disorder [OCD]).
An altered risk of cancer among individuals with mental illness is plausible and potentially attributable to a multitude of factors [10]. Firstly, behavioural and lifestyle factors (e.g., smoking, excessive alcohol use, obesity, poor diet, and physical inactivity), which are more prevalent among individuals with mental illness [38], are also established cancer risk factors [39]. Poorer socioeconomic circumstances (e.g., lower education and income, suboptimal social integration, and greater unemployment) among individuals with mental illness may also exacerbate cancer risk [40]. Detection biases related to mental illness may also contribute to the differing risks of various cancer types observed among individuals with different types of mental illness. Accordingly, mental illness is often accompanied by reduced access to, and quality of, health care [41], potentially making it difficult for individuals with mental illness to be diagnosed with, and treated for, precancerous conditions in a timely manner. As such, individuals with mental illness do not appear to benefit equally from existing preventive strategies for cancer, as evidenced by persistently lower cancer screening utilization [42]. Lower screening participation among individuals with mental illness could result in the reduced detection of cancer, which might partially explain the lower-than-expected risk of rectal cancer among individuals with schizophrenia and of prostate cancer among individuals with schizophrenia, mood disorders, or anxiety disorders. Previous research has indeed indicated that individuals with schizophrenia have lower participation in fecal occult blood testing and even lower completion rates of follow-up colonoscopy [43, 44]. Conversely, the higher-than-expected risk of certain cancer types among individuals with mood or anxiety disorders might be partly attributed to heightened somatic worry and health concerns among these patients, which may increase their healthcare-seeking behaviours and the subsequent likelihood of cancer detection. Further, treatment for mental illness, such as antipsychotic drugs, have been shown to affect cancer risk through weight gain and obesity, hormonal changes [45], and hyperprolactinemia, which can increase the risk of breast cancer [46]. However, protective effects of antipsychotic drugs have also been observed for certain cancers such as prostate cancer [12]. Additionally, as many mental illnesses, especially the severe types, are associated with an increased risk of chronic somatic diseases, competing risk due to non-cancer-related death might also modulate the risk of cancer diagnosis, which could partially explain the inverse association observed between schizophrenia and prostate cancer. Nevertheless, further research is needed to identify which individuals with mental illness are at particularly high risk of cancer and the reasons contributing to this elevated risk, in order to design effective cancer prevention strategies.
Shared genetic liability could also contribute to an increased or decreased risk of cancer among individuals with mental illness [47]. Genome-wide association studies (GWAS) have revealed shared genetic mechanisms underlying multiple diseases, including mental disorders and cancer [24, 48–52]. Like many other diseases, evidence suggests that mental illness and cancer are not caused by genetic or environmental factors alone, but rather by a complex interplay between nature and nurture (or ‘gene-environment interactions’) [53, 54]. Indeed, a large number of studies have examined potential interactions between environmental cancer risk factors and individual genetic predispositions to cancer measured by family history and the presence of specific genes [54]. However, few studies have assessed the effect of the interaction between mental illness and individual genetic predisposition to cancer on subsequent cancer incidence. Interestingly, the risk increment of cancer noted among children with autism has been observed to decline with increasing heritability of cancer type, suggesting that autism may play a greater role in less heritable cancer types [23]. These findings highlight the potential of future family-design studies to disentangle the role of environment and genetics in the comorbidity between mental illness and cancer.
There are many strengths of this review. Firstly, the broad range of types of mental illness included allows for a comprehensive understanding of the associations between mental illness and cancer risk. Additionally, the inclusion of only Nordic register studies in the review increases the validity of our conclusions, as these studies included the entire national population with prospectively and independently collected information on mental illness and cancer, therefore greatly alleviating the risk of selection and information biases. The high quality of the included studies is highlighted in our risk of bias appraisal, whereby the vast majority of studies were classified as being at low risk of bias. Furthermore, we used a robust search strategy to search five research databases, in addition to searching reference lists of eligible studies and relevant systematic reviews, which allowed us to identify all eligible studies, thereby increasing the robustness of our conclusions.
However, some limitations must be noted. Firstly, only studies published in English were included in the review, potentially reducing the generalizability of our conclusions. Our review was also limited by the available data set. Although the use of Nordic register studies diminished the risk of biases, the lack of adjustment for key confounders such as body mass index (BMI) and smoking, due to the lack of such data in the registers, increases the risk of residual confounding. Furthermore, as weight gain is a common side effect of many psychotropic medications, BMI could act as mediator in the associations between mental illness and cancer risk, which was rarely accounted for in the included studies. Additionally, as several of the included studies did not specify whether participants were free of the outcome (i.e., cancer) when the exposure was assessed, temporality issues could have reduced the validity of the observed associations. Therefore, future studies should ensure that cancer has not occurred before the onset of mental illness, for example by using a ‘wash out period’ after the first diagnosis of mental illness to ensure that only incident cancer cases occurring after the exposure are identified. Between-study variations in model adjustments and the ICD definitions used for mental illness also increased heterogeneity and made comparisons between studies difficult. Further, for most of the mental illness types, studies had only been conducted in Sweden and Denmark, meaning that we could not perform meta-analyses for these exposures. However, the narrative syntheses allowed us to describe and compare the findings from the included studies. Finally, caution is needed when generalizing the study findings to other settings, due to the unique healthcare and social welfare systems in the Nordic countries.
In conclusion, this systematic review demonstrates an altered risk of cancer among individuals with certain types of mental illness in the Nordic countries; however, the results vary greatly by cancer type and sex. We call for further focused research to better understand the factors underlying the high comorbidity between mental illness and cancer, with the aim to provide targeted prevention and reduce cancer disparities among people with mental illness.
Supplementary information
References
1.Sung H Ferlay J Siegel RL Laversanne M Soerjomataram I Jemal A Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin 2021 71 209 49 33538338 10.3322/caac.21660 Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.10.3322/caac.21660 33538338
2.Chen S Cao Z Prettner K Kuhn M Yang J Jiao L Estimates and projections of the global economic cost of 29 cancers in 204 countries and territories from 2020 to 2050 JAMA Oncol 2023 9 465 72 36821107 PMC9951101 10.1001/jamaoncol.2022.7826 Chen S, Cao Z, Prettner K, Kuhn M, Yang J, Jiao L, et al. Estimates and projections of the global economic cost of 29 cancers in 204 countries and territories from 2020 to 2050. JAMA Oncol. 2023;9:465–72.10.1001/jamaoncol.2022.7826 PMC9951101 36821107
3.Collaborators GBDMD.Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease study 2019 Lancet Psychiatry 2022 9 137 50 10.1016/S2215-0366(21)00395-3 PMC8776563 35026139 Collaborators GBDMD. Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease study 2019. Lancet Psychiatry. 2022;9:137–50.10.1016/S2215-0366(21)00395-3 PMC8776563 35026139
4.The Lancet Global H..Mental health matters Lancet Glob Health 2020 8 e1352 10.1016/S2214-109X(20)30432-0 PMC7561290 33069297 The Lancet Global H.. Mental health matters. Lancet Glob Health. 2020;8:e1352.10.1016/S2214-109X(20)30432-0 PMC7561290 33069297
5.Lu D Andersson TM Fall K Hultman CM Czene K Valdimarsdottir U Clinical diagnosis of mental disorders immediately before and after cancer diagnosis: a nationwide matched cohort study in sweden JAMA Oncol 2016 2 1188 96 27124325 10.1001/jamaoncol.2016.0483 Lu D, Andersson TM, Fall K, Hultman CM, Czene K, Valdimarsdottir U, et al. Clinical diagnosis of mental disorders immediately before and after cancer diagnosis: a nationwide matched cohort study in sweden. JAMA Oncol. 2016;2:1188–96.10.1001/jamaoncol.2016.0483 27124325
6.Chang WH Lai AG Cumulative burden of psychiatric disorders and self-harm across 26 adult cancers Nat Med 2022 28 860 70 10.1038/s41591-022-01740-3 35347280 PMC9018408 Chang WH, Lai AG. Cumulative burden of psychiatric disorders and self-harm across 26 adult cancers. Nat Med. 2022;28:860–70.10.1038/s41591-022-01740-3 PMC9018408 35347280
7.Zhu J Fang F Sjolander A Fall K Adami HO Valdimarsdottir U First-onset mental disorders after cancer diagnosis and cancer-specific mortality: a nationwide cohort study Ann Oncol 2017 28 1964 9 28525559 10.1093/annonc/mdx265 Zhu J, Fang F, Sjolander A, Fall K, Adami HO, Valdimarsdottir U. First-onset mental disorders after cancer diagnosis and cancer-specific mortality: a nationwide cohort study. Ann Oncol. 2017;28:1964–9.10.1093/annonc/mdx265 28525559
8.Lu D Andrae B Valdimarsdottir U Sundstrom K Fall K Sparen P Psychologic distress is associated with cancer-specific mortality among patients with cervical cancer Cancer Res 2019 79 3965 72 31253667 10.1158/0008-5472.CAN-19-0116 Lu D, Andrae B, Valdimarsdottir U, Sundstrom K, Fall K, Sparen P, et al. Psychologic distress is associated with cancer-specific mortality among patients with cervical cancer. Cancer Res. 2019;79:3965–72.10.1158/0008-5472.CAN-19-0116 31253667
9.Liu Q Song H Andersson TM Magnusson PKE Zhu J Smedby KE Psychiatric disorders are associated with increased risk of sepsis following a cancer diagnosis Cancer Res 2020 80 3436 42 32532824 10.1158/0008-5472.CAN-20-0502 Liu Q, Song H, Andersson TM, Magnusson PKE, Zhu J, Smedby KE, et al. Psychiatric disorders are associated with increased risk of sepsis following a cancer diagnosis. Cancer Res. 2020;80:3436–42.10.1158/0008-5472.CAN-20-0502 32532824
10.Weinstein LC Stefancic A Cunningham AT Hurley KE Cabassa LJ Wender RC Cancer screening, prevention, and treatment in people with mental illness CA Cancer J Clin 2016 66 134 51 26663383 10.3322/caac.21334 PMC4783271 Weinstein LC, Stefancic A, Cunningham AT, Hurley KE, Cabassa LJ, Wender RC. Cancer screening, prevention, and treatment in people with mental illness. CA Cancer J Clin. 2016;66:134–51.10.3322/caac.21334 PMC4783271 26663383
11.Zhuo C Triplett PT Association of schizophrenia with the risk of breast cancer incidence: a meta-analysis JAMA Psychiatry 2018 75 363 9 29516094 PMC5875321 10.1001/jamapsychiatry.2017.4748 Zhuo C, Triplett PT. Association of schizophrenia with the risk of breast cancer incidence: a meta-analysis. JAMA Psychiatry. 2018;75:363–9.10.1001/jamapsychiatry.2017.4748 PMC5875321 29516094
12.Li H Li J Yu X Zheng H Sun X Lu Y The incidence rate of cancer in patients with schizophrenia: A meta-analysis of cohort studies Schizophr Res 2018 195 519 28 28943096 10.1016/j.schres.2017.08.065 Li H, Li J, Yu X, Zheng H, Sun X, Lu Y, et al. The incidence rate of cancer in patients with schizophrenia: A meta-analysis of cohort studies. Schizophr Res. 2018;195:519–28.10.1016/j.schres.2017.08.065 28943096
13.Wang YH Li JQ Shi JF Que JY Liu JJ Lappin JM Depression and anxiety in relation to cancer incidence and mortality: a systematic review and meta-analysis of cohort studies Mol Psychiatry 2020 25 1487 99 10.1038/s41380-019-0595-x 31745237 Wang YH, Li JQ, Shi JF, Que JY, Liu JJ, Lappin JM, et al. Depression and anxiety in relation to cancer incidence and mortality: a systematic review and meta-analysis of cohort studies. Mol Psychiatry. 2020;25:1487–99.10.1038/s41380-019-0595-x 31745237
14.Catala-Lopez F Fores-Martos J Driver JA Page MJ Hutton B Ridao M Association of anorexia nervosa with risk of cancer: a systematic review and meta-analysis JAMA Netw Open 2019 2 e195313 31173122 PMC6563572 10.1001/jamanetworkopen.2019.5313 Catala-Lopez F, Fores-Martos J, Driver JA, Page MJ, Hutton B, Ridao M, et al. Association of anorexia nervosa with risk of cancer: a systematic review and meta-analysis. JAMA Netw Open. 2019;2:e195313.10.1001/jamanetworkopen.2019.5313 PMC6563572 31173122
15.Global Cancer Observatory IAfRoC, World Health Organization. Cancer Today: Europe. 11 March 2025: https://gco.iarc.who.int/media/globocan/factsheets/populations/908-europe-fact-sheet.pdf.
16.Institute JB Checklist for Cohort Studies. Accessed 11 March 2025:https://jbi.global/sites/default/files/2020-08/Checklist_for_Cohort_Studies.pdf.
17.Goplen CM Verbeek W Kang SH Jones CA Voaklander DC Churchill TA Preoperative opioid use is associated with worse patient outcomes after total joint arthroplasty: a systematic review and meta-analysis BMC Musculoskelet Disord 2019 20 234 10.1186/s12891-019-2619-8 31103029 PMC6525974 Goplen CM, Verbeek W, Kang SH, Jones CA, Voaklander DC, Churchill TA, et al. Preoperative opioid use is associated with worse patient outcomes after total joint arthroplasty: a systematic review and meta-analysis. BMC Musculoskelet Disord. 2019;20:234.10.1186/s12891-019-2619-8 PMC6525974 31103029
18.Crump C Winkleby MA Sundquist K Sundquist J Comorbidities and mortality in persons with schizophrenia: a Swedish national cohort study Am J Psychiatry 2013 170 324 33 23318474 10.1176/appi.ajp.2012.12050599 Crump C, Winkleby MA, Sundquist K, Sundquist J. Comorbidities and mortality in persons with schizophrenia: a Swedish national cohort study. Am J Psychiatry. 2013;170:324–33.10.1176/appi.ajp.2012.12050599 23318474
19.Crump C Sundquist K Winkleby MA Sundquist J Comorbidities and mortality in bipolar disorder: a Swedish national cohort study JAMA Psychiatry 2013 70 931 9 23863861 10.1001/jamapsychiatry.2013.1394 Crump C, Sundquist K, Winkleby MA, Sundquist J. Comorbidities and mortality in bipolar disorder: a Swedish national cohort study. JAMA Psychiatry. 2013;70:931–9.10.1001/jamapsychiatry.2013.1394 23863861
20.Ji J Sundquist K Ning Y Kendler KS Sundquist J Chen X Incidence of cancer in patients with schizophrenia and their first-degree relatives: a population-based study in Sweden Schizophr Bull 2013 39 527 36 22522642 10.1093/schbul/sbs065 PMC3627760 Ji J, Sundquist K, Ning Y, Kendler KS, Sundquist J, Chen X. Incidence of cancer in patients with schizophrenia and their first-degree relatives: a population-based study in Sweden. Schizophr Bull. 2013;39:527–36.10.1093/schbul/sbs065 PMC3627760 22522642
21.Karamanis G Skalkidou A Tsakonas G Brandt L Ekbom A Ekselius L Cancer incidence and mortality patterns in women with anorexia nervosa Int J Cancer 2014 134 1751 7 24114497 10.1002/ijc.28495 Karamanis G, Skalkidou A, Tsakonas G, Brandt L, Ekbom A, Ekselius L, et al. Cancer incidence and mortality patterns in women with anorexia nervosa. Int J Cancer. 2014;134:1751–7.10.1002/ijc.28495 24114497
22.Liu Q Adami HO Reichenberg A Kolevzon A Fang F Sandin S Cancer risk in individuals with intellectual disability in Sweden: A population-based cohort study PLoS Med 2021 18 e1003840 34673770 PMC8568154 10.1371/journal.pmed.1003840 Liu Q, Adami HO, Reichenberg A, Kolevzon A, Fang F, Sandin S. Cancer risk in individuals with intellectual disability in Sweden: A population-based cohort study. PLoS Med. 2021;18:e1003840.10.1371/journal.pmed.1003840 PMC8568154 34673770
23.Liu Q Yin W Meijsen JJ Reichenberg A Gadin JR Schork AJ Cancer risk in individuals with autism spectrum disorder Ann Oncol 2022 33 713 9 35430370 10.1016/j.annonc.2022.04.006 Liu Q, Yin W, Meijsen JJ, Reichenberg A, Gadin JR, Schork AJ, et al. Cancer risk in individuals with autism spectrum disorder. Ann Oncol. 2022;33:713–9.10.1016/j.annonc.2022.04.006 35430370
24.Lu D Song J Lu Y Fall K Chen X Fang F A shared genetic contribution to breast cancer and schizophrenia Nat Commun 2020 11 4637 10.1038/s41467-020-18492-8 32934226 PMC7492262 Lu D, Song J, Lu Y, Fall K, Chen X, Fang F, et al. A shared genetic contribution to breast cancer and schizophrenia. Nat Commun. 2020;11:4637.10.1038/s41467-020-18492-8 PMC7492262 32934226
25.Michels KB Ekbom A Caloric restriction and incidence of breast cancer JAMA 2004 291 1226 30 15010444 10.1001/jama.291.10.1226 Michels KB, Ekbom A. Caloric restriction and incidence of breast cancer. JAMA. 2004;291:1226–30.10.1001/jama.291.10.1226 15010444
26.Pettersson D Gissler M Hallgren J Osby U Westman J Bobo WV The overall and sex- and age-group specific incidence rates of cancer in people with schizophrenia: a population-based cohort study Epidemiol Psychiatr Sci 2020 29 e132 32460950 PMC7264860 10.1017/S204579602000044X Pettersson D, Gissler M, Hallgren J, Osby U, Westman J, Bobo WV. The overall and sex- and age-group specific incidence rates of cancer in people with schizophrenia: a population-based cohort study. Epidemiol Psychiatr Sci. 2020;29:e132.10.1017/S204579602000044X PMC7264860 32460950
27.Tian F Fang F Shen Q Ye W Valdimarsdottir UA Song H Stress-related disorders and subsequent cancer risk and mortality: a population-based and sibling-controlled cohort study in Sweden Eur J Epidemiol 2022 37 947 58 10.1007/s10654-022-00898-x 35962878 PMC9529708 Tian F, Fang F, Shen Q, Ye W, Valdimarsdottir UA, Song H. Stress-related disorders and subsequent cancer risk and mortality: a population-based and sibling-controlled cohort study in Sweden. Eur J Epidemiol. 2022;37:947–58.10.1007/s10654-022-00898-x PMC9529708 35962878
28.Dalton SO Mellemkjaer L Olsen JH Mortensen PB Johansen C Depression and cancer risk: a register-based study of patients hospitalized with affective disorders, Denmark, 1969-1993 Am J Epidemiol 2002 155 1088 95 12048222 10.1093/aje/155.12.1088 Dalton SO, Mellemkjaer L, Olsen JH, Mortensen PB, Johansen C. Depression and cancer risk: a register-based study of patients hospitalized with affective disorders, Denmark, 1969-1993. Am J Epidemiol. 2002;155:1088–95.10.1093/aje/155.12.1088 12048222
29.Oksbjerg Dalton S Munk Laursen T Mellemkjaer L Johansen C Mortensen PB Schizophrenia and the risk for breast cancer Schizophr Res 2003 62 89 92 12765748 10.1016/s0920-9964(02)00430-9 Oksbjerg Dalton S, Munk Laursen T, Mellemkjaer L, Johansen C, Mortensen PB. Schizophrenia and the risk for breast cancer. Schizophr Res. 2003;62:89–92.10.1016/s0920-9964(02)00430-9 12765748
30.Dalton SO Mellemkjaer L Thomassen L Mortensen PB Johansen C Risk for cancer in a cohort of patients hospitalized for schizophrenia in Denmark, 1969-1993 Schizophr Res 2005 75 315 24 15885523 10.1016/j.schres.2004.11.009 Dalton SO, Mellemkjaer L, Thomassen L, Mortensen PB, Johansen C. Risk for cancer in a cohort of patients hospitalized for schizophrenia in Denmark, 1969-1993. Schizophr Res. 2005;75:315–24.10.1016/j.schres.2004.11.009 15885523
31.Gradus JL Farkas DK Svensson E Ehrenstein V Lash TL Milstein A Posttraumatic stress disorder and cancer risk: a nationwide cohort study Eur J Epidemiol 2015 30 563 8 10.1007/s10654-015-0032-7 25957083 PMC4519360 Gradus JL, Farkas DK, Svensson E, Ehrenstein V, Lash TL, Milstein A, et al. Posttraumatic stress disorder and cancer risk: a nationwide cohort study. Eur J Epidemiol. 2015;30:563–8.10.1007/s10654-015-0032-7 PMC4519360 25957083
32.Mellemkjaer L Emborg C Gridley G Munk-Jorgensen P Johansen C Tjonneland A Anorexia nervosa and cancer risk Cancer Causes Control 2001 12 173 7 10.1023/A:1008974414116 11246846 Mellemkjaer L, Emborg C, Gridley G, Munk-Jorgensen P, Johansen C, Tjonneland A, et al. Anorexia nervosa and cancer risk. Cancer Causes Control. 2001;12:173–7.10.1023/a:1008974414116 11246846
33.Momen NC Plana-Ripoll O Agerbo E Benros ME Borglum AD Christensen MK Association between mental disorders and subsequent medical conditions N Engl J Med 2020 382 1721 31 32348643 PMC7261506 10.1056/NEJMoa1915784 Momen NC, Plana-Ripoll O, Agerbo E, Benros ME, Borglum AD, Christensen MK, et al. Association between mental disorders and subsequent medical conditions. N Engl J Med. 2020;382:1721–31.10.1056/NEJMoa1915784 PMC7261506 32348643
34.Mortensen PB The incidence of cancer in schizophrenic patients J Epidemiol Community Health 1989 43 43 7 2592890 PMC1052789 10.1136/jech.43.1.43 Mortensen PB. The incidence of cancer in schizophrenic patients. J Epidemiol Community Health. 1989;43:43–7.10.1136/jech.43.1.43 PMC1052789 2592890
35.Wium-Andersen MK Wium-Andersen IK Jorgensen TSH Jorgensen MB Osler M An analysis of the relative and absolute incidence of somatic morbidity in patients with affective disorders-A nationwide cohort study J Affect Disord 2021 292 204 11 34130184 10.1016/j.jad.2021.05.103 Wium-Andersen MK, Wium-Andersen IK, Jorgensen TSH, Jorgensen MB, Osler M. An analysis of the relative and absolute incidence of somatic morbidity in patients with affective disorders-A nationwide cohort study. J Affect Disord. 2021;292:204–11.10.1016/j.jad.2021.05.103 34130184
36.Lichtermann D Ekelund J Pukkala E Tanskanen A Lonnqvist J Incidence of cancer among persons with schizophrenia and their relatives Arch Gen Psychiatry 2001 58 573 8 11386986 10.1001/archpsyc.58.6.573 Lichtermann D, Ekelund J, Pukkala E, Tanskanen A, Lonnqvist J. Incidence of cancer among persons with schizophrenia and their relatives. Arch Gen Psychiatry. 2001;58:573–8.10.1001/archpsyc.58.6.573 11386986
37.Mellemkjaer L Papadopoulos FC Pukkala E Ekbom A Gissler M Christensen J Cancer incidence among patients with anorexia nervosa from Sweden, Denmark and Finland PLoS ONE 2015 10 e0128018 26000630 PMC4441362 10.1371/journal.pone.0128018 Mellemkjaer L, Papadopoulos FC, Pukkala E, Ekbom A, Gissler M, Christensen J, et al. Cancer incidence among patients with anorexia nervosa from Sweden, Denmark and Finland. PLoS ONE. 2015;10:e0128018.10.1371/journal.pone.0128018 PMC4441362 26000630
38.Muirhead L Cancer risk factors among adults with serious mental illness Am J Prev Med 2014 46 S98 103 24512937 10.1016/j.amepre.2013.10.028 Muirhead L. Cancer risk factors among adults with serious mental illness. Am J Prev Med. 2014;46:S98–103.10.1016/j.amepre.2013.10.028 24512937
39.Lewandowska AM Rudzki M Rudzki S Lewandowski T Laskowska B Environmental risk factors for cancer - review paper Ann Agric Environ Med 2019 26 1 7 30922021 10.26444/aaem/94299 Lewandowska AM, Rudzki M, Rudzki S, Lewandowski T, Laskowska B. Environmental risk factors for cancer - review paper. Ann Agric Environ Med. 2019;26:1–7.10.26444/aaem/94299 30922021
40.Kivimaki M Batty GD Pentti J Shipley MJ Sipila PN Nyberg ST Association between socioeconomic status and the development of mental and physical health conditions in adulthood: a multi-cohort study Lancet Public Health 2020 5 e140 e9 32007134 10.1016/S2468-2667(19)30248-8 Kivimaki M, Batty GD, Pentti J, Shipley MJ, Sipila PN, Nyberg ST, et al. Association between socioeconomic status and the development of mental and physical health conditions in adulthood: a multi-cohort study. Lancet Public Health. 2020;5:e140–e9.10.1016/S2468-2667(19)30248-8 32007134
41.McGinty EE Baller J Azrin ST Juliano-Bult D Daumit GL Quality of medical care for persons with serious mental illness: A comprehensive review Schizophr Res 2015 165 227 35 25936686 PMC4670551 10.1016/j.schres.2015.04.010 McGinty EE, Baller J, Azrin ST, Juliano-Bult D, Daumit GL. Quality of medical care for persons with serious mental illness: A comprehensive review. Schizophr Res. 2015;165:227–35.10.1016/j.schres.2015.04.010 PMC4670551 25936686
42.Solmi M Firth J Miola A Fornaro M Frison E Fusar-Poli P Disparities in cancer screening in people with mental illness across the world versus the general population: prevalence and comparative meta-analysis including 4 717 839 people Lancet Psychiatry 2020 7 52 63 31787585 10.1016/S2215-0366(19)30414-6 Solmi M, Firth J, Miola A, Fornaro M, Frison E, Fusar-Poli P, et al. Disparities in cancer screening in people with mental illness across the world versus the general population: prevalence and comparative meta-analysis including 4 717 839 people. Lancet Psychiatry. 2020;7:52–63.10.1016/S2215-0366(19)30414-6 31787585
43.Yarborough BJH Hanson GC Perrin NA Stumbo SP Green CA Colorectal cancer screening completion among individuals with and without mental illnesses: a comparison of 2 screening methods Am J Health Promot 2018 32 925 31 29214818 10.1177/0890117116686573 PMC7104624 Yarborough BJH, Hanson GC, Perrin NA, Stumbo SP, Green CA. Colorectal cancer screening completion among individuals with and without mental illnesses: a comparison of 2 screening methods. Am J Health Promot. 2018;32:925–31.10.1177/0890117116686573 PMC7104624 29214818
44.Thomsen MK Jorgensen MD Pedersen L Erichsen R Sorensen HT Mikkelsen EM Mental disorders, participation, and trajectories in the Danish colorectal cancer programme: a population-based cohort study Lancet Psychiatry 2023 10 518 27 37353263 10.1016/S2215-0366(23)00179-7 Thomsen MK, Jorgensen MD, Pedersen L, Erichsen R, Sorensen HT, Mikkelsen EM. Mental disorders, participation, and trajectories in the Danish colorectal cancer programme: a population-based cohort study. Lancet Psychiatry. 2023;10:518–27.10.1016/S2215-0366(23)00179-7 37353263
45.Damjanovic A Ivkovic M Jasovic-Gasic M Paunovic V Comorbidity of schizophrenia and cancer: clinical recommendations for treatment Psychiatr Danub 2006 18 55 60 16804500 Damjanovic A, Ivkovic M, Jasovic-Gasic M, Paunovic V. Comorbidity of schizophrenia and cancer: clinical recommendations for treatment. Psychiatr Danub. 2006;18:55–60.16804500
46.Rahman Sahrmann T Olsen MA JM Nickel KB Miller JP Ma C Risk of breast cancer with prolactin elevating antipsychotic drugs: an observational study of US women (Ages 18-64 Years) J Clin Psychopharmacol 2022 42 7 16 34864772 PMC8688205 10.1097/JCP.0000000000001513 Rahman, Sahrmann T, Olsen MA JM, Nickel KB, Miller JP, Ma C, et al. Risk of breast cancer with prolactin elevating antipsychotic drugs: an observational study of US women (Ages 18-64 Years). J Clin Psychopharmacol. 2022;42:7–16.10.1097/JCP.0000000000001513 PMC8688205 34864772
47.Gold SM Kohler-Forsberg O Moss-Morris R Mehnert A Miranda JJ Bullinger M Comorbid depression in medical diseases Nat Rev Dis Primers 2020 6 69 32820163 10.1038/s41572-020-0200-2 Gold SM, Kohler-Forsberg O, Moss-Morris R, Mehnert A, Miranda JJ, Bullinger M, et al. Comorbid depression in medical diseases. Nat Rev Dis Primers. 2020;6:69.10.1038/s41572-020-0200-2 32820163
48.Visscher PM Wray NR Zhang Q Sklar P McCarthy MI Brown MA 10 years of GWAS discovery: biology, function, and translation Am J Hum Genet 2017 101 5 22 28686856 PMC5501872 10.1016/j.ajhg.2017.06.005 Visscher PM, Wray NR, Zhang Q, Sklar P, McCarthy MI, Brown MA, et al. 10 years of GWAS discovery: biology, function, and translation. Am J Hum Genet. 2017;101:5–22.10.1016/j.ajhg.2017.06.005 PMC5501872 28686856
49.Yuan K Song W Liu Z Lin GN Yu S Mendelian randomization and GWAS meta analysis revealed the risk-increasing effect of schizophrenia on cancers Biology (Basel) 2022 11 1345 36138824 PMC9495962 10.3390/biology11091345 Yuan K, Song W, Liu Z, Lin GN, Yu S. Mendelian randomization and GWAS meta analysis revealed the risk-increasing effect of schizophrenia on cancers. Biology (Basel). 2022;11:1345.10.3390/biology11091345 PMC9495962 36138824
50.Wu X Zhang W Zhao X Zhang L Xu M Hao Y Investigating the relationship between depression and breast cancer: observational and genetic analyses BMC Med 2023 21 170 10.1186/s12916-023-02876-w 37143087 PMC10161423 Wu X, Zhang W, Zhao X, Zhang L, Xu M, Hao Y, et al. Investigating the relationship between depression and breast cancer: observational and genetic analyses. BMC Med. 2023;21:170.10.1186/s12916-023-02876-w PMC10161423 37143087
51.Chen X Kong J Diao X Cai J Zheng J Xie W Depression and prostate cancer risk: A Mendelian randomization study Cancer Med 2020 9 9160 7 33027558 PMC7724297 10.1002/cam4.3493 Chen X, Kong J, Diao X, Cai J, Zheng J, Xie W, et al. Depression and prostate cancer risk: A Mendelian randomization study. Cancer Med. 2020;9:9160–7.10.1002/cam4.3493 PMC7724297 33027558
52.Zhu GL Xu C Yang KB Tang SQ Tang LL Chen L Causal relationship between genetically predicted depression and cancer risk: a two-sample bi-directional mendelian randomization BMC Cancer 2022 22 353 10.1186/s12885-022-09457-9 35361153 PMC8973550 Zhu GL, Xu C, Yang KB, Tang SQ, Tang LL, Chen L, et al. Causal relationship between genetically predicted depression and cancer risk: a two-sample bi-directional mendelian randomization. BMC Cancer. 2022;22:353.10.1186/s12885-022-09457-9 PMC8973550 35361153
53.Tsuang MT Bar JL Stone WS Faraone SV Gene-environment interactions in mental disorders World Psychiatry 2004 3 73 83 16633461 PMC1414673 Tsuang MT, Bar JL, Stone WS, Faraone SV. Gene-environment interactions in mental disorders. World Psychiatry. 2004;3:73–83.PMC1414673 16633461
54.Mbemi A Khanna S Njiki S Yedjou CG Tchounwou PB Impact of gene-environment interactions on cancer development Int J Environ Res Public Health 2020 17 8089 33153024 PMC7662361 10.3390/ijerph17218089 Mbemi A, Khanna S, Njiki S, Yedjou CG, Tchounwou PB. Impact of gene-environment interactions on cancer development. Int J Environ Res Public Health. 2020;17:8089.10.3390/ijerph17218089 PMC7662361 33153024
Come citare questo studio
Xue Xiao, Fatemeh Sadeghi, Gillian Murphy, Zhe Zhang, Ole A Andreassen, Unnur Valdimarsdóttir, Fang Fang, Mary M Barker. (2026). Cancer risk among individuals with mental illness - a systematic review and meta-analysis of nordic register-based prospective studies.. Translational psychiatry. DOI: 10.1038/s41398-026-04351-5
Consulta la pubblicazione originale ↗